A Phase 3, Randomized, 3-Part Study to Investigate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)
Phase of Trial: Phase III
Latest Information Update: 20 Jan 2019
At a glance
- Drugs Dupilumab (Primary)
- Indications Eosinophilic oesophagitis
- Focus Registrational; Therapeutic Use
- Sponsors Regeneron Pharmaceuticals
- 30 Oct 2018 Planned End Date changed from 24 Feb 2023 to 6 Jan 2023.
- 30 Oct 2018 Planned primary completion date changed from 5 May 2022 to 21 Mar 2022.
- 03 Oct 2018 Status changed from not yet recruiting to recruiting.